Vobarilizumab

Vobarilizumab
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized
Target	IL6R
Clinical data
Other names	ALX0061
ATC code	none;
Identifiers
CAS Number	1628814-88-9;
ChemSpider	none;
UNII	9OD8ISS64U;
KEGG	D11005;
Chemical and physical data
Formula	C1118H1757N315O364S8
Molar mass	25691.68 g·mol−1

Vobarilizumab (INN; development code ALX0061) is a humanized bispecific nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.[1][2][3]

This drug was developed by Ablynx NV to block interleukin-6 receptor. Vobarilizumab has been evaluated in patients with rheumatoid arthritis[4] as well as in Lupus.[5]

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.
World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
Hassan N, Choy E (September 2020). "Interleukin-6 inhibitors". In Scott DL, Galloway J, Cope A, Pratt A, Strand V (eds.). Oxford Textbook of Rheumatoid Arthritis. Oxford University Press. p. 394. doi:10.1093/med/9780198831433.003.0032. ISBN 978-0-19-256710-9.
"A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies with ALX-0061". 19 July 2019.
"A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus". 12 February 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.

[2] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).

[3] Hassan N, Choy E (September 2020). "Interleukin-6 inhibitors". In Scott DL, Galloway J, Cope A, Pratt A, Strand V (eds.). Oxford Textbook of Rheumatoid Arthritis. Oxford University Press. p. 394. doi:10.1093/med/9780198831433.003.0032. ISBN 978-0-19-256710-9.

[4] "A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies with ALX-0061". 19 July 2019.

[5] "A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus". 12 February 2019.